Clinical Trials Browser

Recurrence

NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Phase 2 Completed

43 enrolled 11 charts

Endocrine

Carcinoid Tumor

NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Phase 2 Completed

46 enrolled 7 charts

EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT04027348 2022-11-29

Palliative Management of Inoperable Malignant Bowel Obstruction

Phase 2 Terminated

15 enrolled 10 charts

Intestinal Obstruction

NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Phase 2 Completed

150 enrolled 12 charts

Vipoma

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Phase 2 Completed

43 enrolled 12 charts

EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Phase 2 Terminated

62 enrolled 25 charts

Breast

Breast Neoplasms, Diarrhea, Neoplasms

NCT02021942 2018-02-05

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Phase 2 Completed

16 enrolled 11 charts

Thoracic

Primary Inoperable Thymoma

NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Phase 2 Completed

43 enrolled 9 charts

Endocrine

Carcinoma, Neuroendocrine

NCT00510224 2013-12-11

Sandostatin for Patients With Androgen Independent Prostate Cancer

Phase 2 Terminated

13 enrolled 4 charts

Genitourinary

Prostatic Neoplasms

NCT00332696 2011-09-23

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Phase 2 Completed

64 enrolled 17 charts

Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

NCT00005906 2010-04-30

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

Phase 2 Completed

4 enrolled 8 charts

Thoracic

Ascites, Chylous Ascites, Chylothorax, Lymphangiomyoma, Pleural Effusion, Lymphangioleiomyomatosis

Clinical Trials

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Palliative Management of Inoperable Malignant Bowel Obstruction

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Sandostatin for Patients With Androgen Independent Prostate Cancer

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis